Drug Sales Trends for DIOVAN

Payment Methods and Pharmacy Types for DIOVAN (2004)

Revenues by Pharmacy Type

Pharmacy Type	Revenues
MAIL-ORDER	$205,517,621
INSIDE ANOTHER STORE	$404,665,634

Units Sold by Pharmacy Type

Pharmacy Type	Units
MAIL-ORDER	2,248,198
INSIDE ANOTHER STORE	5,649,611

Revenues by Payment Method

Payment Method	Revenues
MEDICAID	$188,156,585
MEDICARE	$57,759,980

Select year for charts:

[2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 ]

Annual Sales Revenues and Units Sold for DIOVAN

These sales figures are drawn from a US national survey of drug expenditures

Drug Name	Revenues (USD)	Units	Year
DIOVAN			2022
DIOVAN			2021
DIOVAN			2020
DIOVAN			2019
DIOVAN			2018
DIOVAN			2017
DIOVAN			2016

Market Analysis and Sales Projections for DIOVAN (Valsartan)

Last updated: February 12, 2026

DIOVAN (valsartan) is an angiotensin II receptor blocker (ARB) prescribed primarily for hypertension and heart failure management. Its global market dynamics are driven by prevalence rates of cardiovascular diseases, regulatory approvals, and competitive landscape.

Market Overview

Global Market Size

• The global ARB market was valued at approximately USD 16 billion in 2022.
• DIOVAN's market share has historically ranged between 20-25% within the ARB class, equating to a share value of USD 3.2-4 billion as of recent data.

Geographic Distribution

• The United States accounts for roughly 35% of ARB sales, with Europe contributing another 25%.
• Emerging markets in Asia and Latin America are experiencing rapid growth due to increasing healthcare infrastructure and hypertension prevalence.

Prescription Trends

• DIOVAN's prescriptions have grown steadily, with a CAGR of approximately 3-5% globally over the past five years.
• Patent expiration in multiple markets, including the US (2018), has led to increased generic competition, impacting sales volume but reducing pricing.

Competitive Landscape

• DIOVAN faces competition from generic valsartan, other ARBs like losartan and olmesartan, and combination therapies.
• Market shifts post-2018 saw generic versions, lowering prices by 50-70% depending on the region.

Sales Drivers and Risks

Drivers

• Rising hypertension prevalence, forecasted to reach 1.39 billion globally by 2030.
• Expanding adoption in heart failure and post-myocardial infarction therapy.
• Patent expiry leading to affordable generic alternatives.

Risks

• Regulatory challenges and recalls related to valsartan contamination (e.g., nitrosamine impurities).
• Patent protections expiring in key markets, reducing premium pricing.
• Competition from new drug classes, including SGLT2 inhibitors and novel antihypertensives.

Sales Projections (2023-2027)

Year	Estimated Market Share	Global Sales (USD billion)	Comments
2023	15-20%	1.5-2.0 billion	Post-patent expiry, generic dominance, price pressure
2024	12-18%	1.2-1.8 billion	Continued generic penetration, slight market share decline
2025	10-15%	1.0-1.5 billion	Market stabilization, increased competition from new ARBs
2026	8-12%	0.8-1.2 billion	Margins under pressure, generic saturation
2027	6-10%	0.6-1.0 billion	Market contraction expected as alternatives gain favor

Key Factors Impacting Future Sales

• Patent Expiries: Major markets have seen patent losses, increasing generic sales, though branded DIOVAN retains a preference in certain select markets for its brand reputation and formulation stability.
• Market Penetration of Generics: The majority of sales now originate from generics, which have reduced pricing but expanded volume.
• New Therapeutics: Emerging drugs with superior efficacy or fewer side effects may replace traditional ARBs, impacting sales trajectories.
• Regulatory Environment: Ongoing monitoring of manufacturing standards and safety concerns remains critical, especially following past contamination issues.

---

Conclusion

DIOVAN's market share is declining due to patent expirations and increased generic competition. Despite this, the drug maintains a significant volume in markets where branded medications are preferred. Future sales are projected to decrease gradually but may stabilize with strategic branding, differentiated formulations, or expanded indications.

---

Key Takeaways

• The global ARB market was valued at USD 16 billion in 2022, with DIOVAN accounting for approximately USD 3.2-4 billion pre-patent expiry.
• Patent losses have shifted sales toward generics, reducing prices but increasing volume.
• Sales are expected to decline from USD 1.5-2 billion in 2023 to around USD 0.6-1 billion by 2027, reflecting increased competition.
• Major growth drivers include the rising prevalence of hypertension and expanding markets in Asia and Latin America.
• Risks include safety concerns, regulatory actions, and the rise of new antihypertensive therapies.

---

FAQs

1. What factors primarily influence DIOVAN's market share?
   Patent status, regulatory safety issues, competitive generic pricing, and emerging drug options affect its market share.

2. How has patent expiration impacted sales?
   It introduced generic versions, leading to a significant price decrease but increased volume early on. Over time, the branded DIOVAN market share has declined.

3. What regions offer the most growth opportunities?
   Asia-Pacific and Latin America demonstrate the fastest growth due to rising hypertension rates and improving healthcare access.

4. Are there ongoing regulatory concerns about DIOVAN?
   Yes. Past contamination issues with nitrosamines have led to recalls and increased regulatory scrutiny.

5. What therapeutic areas could expand DIOVAN's use cases?
   Expanding indications into heart failure and kidney protection could offset declines tied to hypertension marketing.

---

References

1. IQVIA, "Global ARB Market Report," 2022.
2. FDA, "Valsartan Recall and Safety Notices," 2018-2022.
3. WHO, "Cardiovascular Disease Statistics," 2023.